<SUBMISSION>
<ACCESSION-NUMBER>0001193125-06-242931
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20061127
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20061128
<DATE-OF-FILING-DATE-CHANGE>20061128
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AtriCure, Inc.
<CIK>0001323885
<ASSIGNED-SIC>3841
<IRS-NUMBER>341940305
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-51470
<FILM-NUMBER>061242738
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
<PHONE>513-755-4107
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML><HEAD>
<TITLE>Current Report</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): November&nbsp;27, 2006 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>AtriCure, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR
WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-51470</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>34-1940305</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>6033 Schumacher Park Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>West Chester, OH</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>45069</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (513)&nbsp;755-4100 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or
former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal
Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We announced today that Gene R. McGrevin resigned from our Board of Directors, effective December&nbsp;1, 2006. The
resignation did not involve any disagreement with us concerning any matter relating to our operations, policies or practices. At the time of his resignation, Mr.&nbsp;McGrevin was a member of our Compensation Committee. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A copy of the press release announcing Mr.&nbsp;McGrevin&#146;s resignation is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference in its entirety. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of November 28, 2006.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ATRICURE, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ David J. Drachman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">David J. Drachman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Dated: November&nbsp;28, 2006 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT LIST </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of November 28, 2006.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g41616img001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Contacts: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>AtriCure, Inc.</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">David J.
Drachman</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(513)
755-5758</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">ddrachman@atricure.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>The Ruth Group</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nick Laudico
(investors)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(646) 536-7030</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">nlaudico@theruthgroup.com</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Jason Rando (media)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">(646) 536-7025</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">jrando@theruthgroup.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Press Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AtriCure Director Gene McGrevin Resigns to Devote Himself to New Position </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">WEST CHESTER, Ohio &#150;
November&nbsp;28, 2006 &#150; AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today the resignation of Gene R. McGrevin from the Company&#146;s Board of
Directors, effective December&nbsp;1, 2006. Mr.&nbsp;McGrevin has recently been appointed Chairman of the Board at a privately-held medical device company that plans to file for an initial public offering on a European exchange. In this
newly-appointed position, Mr.&nbsp;McGrevin has committed a majority of his time to the privately-held company&#146;s IPO process and subsequent operational responsibilities. The resignation did not involve any disagreement with the Company
concerning any matter relating to the Company&#146;s operations, policies or practices. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">AtriCure&#146;s Board composition remains in full compliance with
all corporate governance requirements of the Nasdaq Stock Exchange. The resignation brings AtriCure&#146;s Board to a total of eight members, six of whom are independent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Richard M. Johnston, AtriCure&#146;s Chairman of the Board of Directors, said, &#147;We thank Gene for his contributions to our Board and wish him luck on his challenging new endeavor. As the majority of our Board is
currently independent, we do not anticipate filling the vacancy created by Gene&#146;s resignation at this time.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
SIZE="2"><U>About AtriCure, Inc. </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical
devices to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure bipolar ablation system as a standard treatment alternative during open-heart
surgical procedures to </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that
cause atrial fibrillation, a rapid, irregular quivering of the upper chambers of the heart. Atrial fibrillation affects more than 2.4&nbsp;million people in the U.S. and predisposes them to a five fold increased risk of stroke. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The FDA has cleared the AtriCure bipolar ablation system for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures but to
date has not cleared or approved the system for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure Isolator</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(TM)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"> Transpolar</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(TM)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Pen for the ablation of cardiac tissue and the evaluation of cardiac arrhythmias,
but the Isolator</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>(TM)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Transpolar</FONT><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>(TM)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Pen has not been approved for the treatment of AF. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press
release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects,
believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure&#146;s products. Forward-looking statements are
based on AtriCure&#146;s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which
are beyond AtriCure&#146;s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure&#146;s products, AtriCure&#146;s ability to develop and market new and enhanced products, the timing of and ability to
obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure&#146;s products, competition from existing and new products and procedures or
AtriCure&#146;s ability to effectively react to other risks and uncertainties described from time to time in AtriCure&#146;s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers,
litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to
publicly update any forward- looking statement, whether as a result of new information, future events or otherwise. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g41616img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41616img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P$$`P$1``(1`0,1`?_$`,X```$%``,!`0$`````
M```````&!P@)"@($!0$#"P$!```'`0$```````````````$"`P4&!P@)!!``
M``8!`@0#!`4%"0@3`````0(#!`4&!P`1(1(3"#$4"4$B%1;P46$R%W$U=A@*
M@9&A4F(C)#<90C-3-+2U1CC!T>'QDJ*S1%1TA)2D=975)C98$0`!`P,"!`,&
M!`0#!`L````!``(#$00%(08Q01('(A,(46%Q@3(4D:$5%T)2(S."DA:Q<J(8
MT>'Q8M)CDZ/31&3_V@`,`P$``A$#$0`_`-_&B(T1=5Z\;1S)Y(/52H,V#9P\
M=+G^ZBV:I'775-M_<II$$1^P-$6<RS]Q]U>=P+[,D?-/TC-+1SQ3('9S,25E
MBMY1&,%(/YHS%TQ(8P@)1$>H/'7TAIZ>A4B=:K1)7)V/M%?A+)%*`M&3\4PF
M&"FX#S-)%JD[0$VW`#@FJ`"'L'?7S%55[.B(T1&B(T1&B(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T10][XLF#CO!$\
MV9.10G+HJE5HL$SB1P5%T('E7*6WWB),R],X;^"P:G8*N4KN"SX@BH1`%2IG
M!OS`AU.0PI=3E$02YP`2\_3#?;Q^K5=2*]3T\\G?.&'5Z6^<BM,X[DU6(%.;
MF5-`2IU'T2J<1'?9-P+E$H>PB)>.J#Q0U]JG::BBGYJ13(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T149
M^HIDT+7EN.HC!8ZT;CR,Z#E-,PJ)GL4R1-V],F4OBJBSZ*!B["(*)B&J\8H*
ME4W'52J1[8"F[(0HXQJ0WA2''((*D12.[&RB)98C-)QTP7(FLR(5`2B.X`80
MU+U4DUX*-*M]Z@IV.9/_``YSK"L'BPH0M[2/4Y$%#<B*3QP<%XAP<HB`"J20
M1!`OM#KC]>JDC:MJ.2@TZK0;^7QU\RJ(T1?!';[`\1$?``#QT1)NOW&KVM:9
M;UN=CIM2OO\`X7,_#ERN4V$AR=06BJR>Z1EBDXB!3&V\!XZ41*71$:(C1$:(
MH$=\G<7>\'Q5-B<?]"/EK<I+K.+`[8(/TV3.*!D0S5FBZ`[<7;DS[F$QB[IE
M(`EXCJHQH=4GDI7$B@"]CLD[@KIG*I64E[3;.IJJR;=H$XR9E8I239VV(NF1
MRW1*5L1Z@(COR`7F(("(;\=0>T#@C353?U(IDVN6<O8XP919K)65K;$4NF0*
M/4?S$NY(@D94P#T&3-,1ZKV1=F*)4D$BF4./@&P"(77"8/*[BR4>)PT+[B^E
M/A:T<N9<>`:.)<:`*Q[CW)@]IXB7.;BN8[7&0CQ/>:"O)H'%SG<FC4K/5D_U
MVLE9/N:^/.Q'MOF<BN0,=%*QVV(F)23>$.(`E(,JM7%R)0J`&`P`:0<*)GX<
M`\-=.8?TZXG$6`R?<7*,MF\XXG-:T4Y&20>+_`T%<8Y_U;9S/Y,X;M)A)+U_
M`2RL>]Y!X.$,1HP5J/ZCC[P.";"5[EOVA(ZQYE+"4Q$Q28$=&BVN),:/4O+@
M;JF3$7+IU,#S)F`H[#S@4-^!MQU=H=J^F4`0.OV/FU%3<SC6G'2C>.OL5CN-
M\>LG6Z&,>R`:]+;.W(I[""'//L-"#\#JF^C/70[Y\&61O7>Y7`E;>B10//LY
MJL3^.[*L@B80<'AE2*)0JYA$-N?H+I`.KI-Z>.WFXK,WFT\C*T4'26R,GCJ?
MY]"X?#J!5CM_5EW9VG?"QWUB8''JHX20R6TE!Q+"#TGX]!"U&X`RZPSYA?&N
M98R(<U]CD:JQUG;PCQVB^<Q0/2F`[%=ZW(F@Z405(8HG*4H&VWV#PUQ_N7"2
M;;S]W@I9!+):S.C+P"`ZG,`ZBHY+OW9NY8=X;6L-SP1.ABOK9LHC)#BSJ_A+
MAH2/:`$\6K(LE1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$2;N-FCZ95+%;)50$H
M^NPTE,.C"(`(I,&BKD2$W$-U%.GRE#Q$1VU$"IHBSZ8,K4IW$]RT8XFBG<DE
M[._O-J5#=0J4>S=#)J$'J>*2CLZ*(%';W#B`>&J[G4914QJ5HK!-,J8(E3*"
M12`D"8``$!,"\H$`O@!>4-MM?.JBSD=T6/7F%\^65E$\[%JM)H7:IN$B"F5!
MM).!DD/*`!2@0D5*$40)MX='VZ^AAJS74*F=':*^7".0FN4L5TN[-3E,I+PC
M,9!,#\QFTJW2(A(ME1X[*I.B&Y@^L=4'"AHIQJ$Z9U$TBB=0Y$R!MS'4,4A2
M[CL&XF$`#<=045`WU`+]9*CA^,^4+$ZAE)RP)1DFXB71473B/,B)U&P.$QZB
M*:H_>$HE$0X;ZJ1BI*E<=$C_`$TC&/BZ\',<3G/<@.<YC"<QS&:&,8QS&W,8
MQA'<1$1$1^W27ZZ<J*#%9)]/MU34ZX**$2*)U#D3(`<3G,4I0^T3&$``-OMT
M1=-E*QDFBLXC9!D_0;KJM5UF;I%PBBX0VZR*BB1SD*HEN',41W#1%UD['7UG
M8,$IR(5?"?I`S3DF9W0J@&XI@@585!.'U;;ZC0\>2))Y*Q10<MPJ<#?Z^TG6
M#=;S30RVZ;EBXVY3+-'*8E41,<G`P;B4P>(#L&P.+>"@0.:ZN*Z7C+'T(\JF
M,&4,PCXQ^8LPWBG*3MP$NHBFHH:67*HHH:0.@)!$#B`@40V``T<2?J04Y)P)
M*28P\<^EI5VW81L6S<R$B^=JD0;,V3-$[ATY<+*"5-)%!!,QC&$0``#<=30Q
M2W$K88&ETKW!K6@$DN)H`![2=`J<\\-K`^YN'!D$;2YSB:`-:"22>0`%22L1
M_<QGO,'J]=[59PAC63?1^(R6IU!XXA!!TC%1M7CO?GLG6EF!Q2<2SIDU473%
M8H`@"B38H@(B8WH%M+;>#[']OY=P99K79SR`^=VA<Z1WT6\9Y-!(!`XT<\^[
MRIWUO#<OJ2[J0;4PDCV;:^X=';,U#&Q-^NYE%:%[@TNJZE`6QBE376]VK=HN
M%NT#'$3C[$U99,UF[)%*Q7!TU;*6RX2(`!W4E.RI4RKJ]=P',F@4P(HE`I2E
MW#<>*-Y;WS^^,J_)9J9Q:7>"($^7$WDUC>`H.)XGB5Z.]O>V^U^VN#CPVW8&
M->&#S9B!YTSN)=(^E34\&CPM%`!S4H=M8BL^46^[;M5Q5W9XAMF.<D5>-E';
MR%?!5;+Y)O\`,=5GDVZZD5)PDH9(734R#TP"9(#"DJ41`Q1UE^R=YYG9>;AR
MN+F>R-LH\QE3T2,J.IKV\#4<#2HY%8#W&[?;?[B[;N,)FH&22NB=Y,O2/,BD
MH>ES'4J*'B/I=J""D-Z<=3MM![*<$4:\PSZ!ME.A++5IB,D6[AJY(M`WRU1:
M#SH.R)N"-91FU3=("(!S(+$,'`0U<>ZM]8Y+N!D<EC7MDLKB2.1CFD$4?%&X
MBHTJTDM=[P59NQV-R.&[58?$9:)\.0M8I8GM<""#'<3,!H16CP`YNFK7`\%+
M:QW.IT]-DM:[-!5Q*2?M(J/--2C*-![)OU.BR8-`=K)"X=NU0Y4TR[F,/@&L
M)M;&]OG.;9122EC2YW2TNZ6@5)-!H`.)6R+[*8S&-8[(W$,#9'AC?,>UO4YQ
MHUK:D5<>0&I2G#7RA?>N)C`7<3"!2E#<3"(`4`#B.XCP`-M-:BB@334\$F8F
MZ5&?F9NNP=G@9B>K8,QL$1&2K)_(P@2!#J,?BK1JLHLQ%V1,PD!0"B8`';7U
MSV%];01W5Q#+';2UZ'.:0U_2=>DD4-.=%\-ME<;>74ME:7$,MY!T^8QKVN='
MU:MZP"2VH!I6E4I1-R@)C"!2@`B(FX`4`\1,([````:^3W<U]Q(`J>"13')>
M/92X.\?1EVJ\E>6$46<?5*/G(YY8&,.=86Q)-Y%MUU';5D=P'("ARE*)^`<=
M7"3$Y2&Q&4FMYF8US^@2N8X,+J5Z0XBA--:`UHK7#G<-<9-V&@N[>3*LCZW0
MM>UTC65IU.:"2&DZ5(`KHO+O.9L2XR%`N1,F46D&<GY&Y+3:(:$46-N`;)IR
M#Q`YAW,`>'MU5QV"S>7J,7:7%Q05/EQO?I\@5\^6W/MS`T&;O[2T+M`)961D
M_)S@E['R+*68LY.+>MI&-D&R+QB_9+IN&CQHX3!5NY:N$1,DN@LF8#%.41`P
M#PU;98Y(9'12M+9&$AP(H01H00>!"O$,T5Q$RXMW-?`]H+7`@AP(J""-""-1
M1>';[S3<?Q#BP7FUUVGP;0@J.9:R3#"&8(IE^\8[F0702V#[!U]%EC[_`"4[
M;;'PRSW#C0-8TN)^302ODR>6Q>&M77N6N(;:T:*E\KVL:/FX@*',EZG/85%R
M2$6MW18I<K.%540<1MB;R4<D=$G.8R\DRZS)%(VVQ3F.!3CP`=9W%VC[D30F
M9N'O0T"M',+7'X--#\J56L)^_G9ZWN!;OW!CW.)(JV0.:*>US:M`]AK0\E*C
M&N8,5YCA@L.*,C4W(D(.P#)4^PQD\U(([[%5/'N%Q1/]AP`=PV]@ZP[*X/,X
M*X^US5K<6MQ_+(QS#_Q`5^2V)@]S;>W-;"]V]>VM[:?S0R-D'SZ2:?`T3C_N
M_P``ZM2O>BY:(J\?47R9\KXIC*$Q<"G*7Z5(#HA#BFJ6OPYBNWJ@&+N(D6?>
M72,'#<AQWX;AJI&*FJE<:)&>FMC(8VJ6O*<@VY7%E?$@8!0Y0'EB8@3^?<(F
M'B7S,DH9,P!P'H!J,IJ:*#1S5H.J2G5:7J1XP^-T.N9/CFH&?TU^:*FUB%]\
MU?EQ#RZJY_`$8^3(``'UNAU5B=0T/TJ5PJ/>D?Z:.3>JPN6)7ZXB9BL%LKY#
MGV*#9X8B$LV1*/$R@.@!8WU`;20<U!IY*Q/+F-FF7*',4)_-2T`RF3L#.)&$
M.BG($*P?MY`B:1UTU"E*HLV*!N&^VJ8-#53$551_=UVPQ6$,?0<W'7^\6@'<
M^2.+&6-\@O'MB&1YA700113`JX#[?;JLUW4I"*+V.R/!;C)U,LLVEE?*5!29
MV`C%>-H%C&";/]FISD<.?YE<IER#P`PE'@(_7J$IHZE!P46C16(U7MZ>5::B
M)@<YYQGTHE=-48:Q6N.D(F233()/+2200:2[A$^X"(@H4X[>/CJF75%*!1Z?
MBH)>H;&6&DO:],Q61,@J-;K(2H2-;<6-S\MM"HMRF22C8IL#=)ND4H"78>?<
M!'<=QU/&>7-0<F5[?RYSS92&F"L8R0TJH5YT]F;M;"/'+<[P\LL(M&*BS4@.
M3$Y$A`C5,X%5V,90^P%`)G=+34C50%3H%(2H^GO>,=Y%H%TBK[#6=K7K-&2T
MN@LQ=03TC9$QQ=J,C"YDTW3@AC[E`YD^?ZP'AJ'F"E"$Z2NCWS*Y0Q"2L.(#
M->1WL9=W,\C(1CR09,09`R*S5118.8)A$J%9BD\,02'YS"!0W,/$=090UTU4
M7)X?3:446P]:UEE#JJJWQ\=150YCJ*'-&L!,<YS")C',([B(CN(ZA)Q'P46I
M(>L/EJ2Q%V#9F?0KDS:8NS>(QJV.4W(<S&ZR:$/8"E-Q,4PUY5UL(<=]O#QU
MMGL9A8LWW*L([AM8;<NG/QB:7,_XPU:$]36XY]M]GLI):NZ;F[#+8<O#.X,D
M_P#;+U3C^SF8LC9/(F?LOOVA%9"J5VLTNNNS)%,=J-C<2,A82IK&W,GUV\:S
M`Q2[;@''6]O5-F9(\5C,'&?Z<TLDKQ[>@-:S\"YRYC]$>WX;C-YG<TK09;>"
M*&,^PRESI/R:SXK6;L&N+*+T97W1%\VTHB063:4KD6CV"F(VZVT,\ZU(W^:Z
M)(MXFUQ`).$7!U8>1<M'J31=<B(I&-TS#TSFV$!V$+AB;\8K(Q7Y@@N!&ZOE
MS-+XG:$4<T%M0*UI7B.:L^?Q3LWB)L6VYN;-TK0/.MW!DS*$&K'$.`)I0FG`
MFE#JL%&(LAY/NO?MAN+R1E#(.33U7/#.$BI&_6N8L[Y%I'SJ[1+D4E';@J`G
M22#F!,"%W\`#7I#G,7A\?VXOY<39VMHV;'%[FPQMC:26`\&@5]U=5Y`;:S6?
MRG>#&V^<O[V_-OEF,8ZXF?*X!LO2*%[C2H&M*!?T%=>9R]EU09Z[\->J)@J"
MS]0\Y9KHTLC<:EBUU1Z??)"MX^E8.>0M,J]D):#B"LUY&<\PQ(4JZJY@!+W!
M+RE+R])>G.?&Y'<4FVLECL?<0&"2X$TL(DG:YAC:UK7NJ&L\7`#CKQ)7'WJY
MM,MBMIQ;QQ&6RMI<-N([4P0W#HK=['MFD+GQLZ2Z2K0.ISCX=*4HF"_9QW;N
M0ANZI\_<N'SUY9Z,X=.W:RCARY75C)0ZBRZZQCJ*JJ''<3"(B(^W61^J:-D5
MSAXXP&L$4P`&@`JWA3@%B'HDEDFL\]-,YSIG2P$DFI)(D))/$FO,JQ/U<L8V
M"5[6<FY@K.:<R8VF<65!%Y&U['US7K-4L:KJQQC-S\V,&"";Z7`[.0.0I?,D
M*42D';@.^L>R67M8=XV>"O,?87<%Y.0Y\T0?(RC'$>67$M;0M!/A-:GW+='J
M1P%[<]OK_<]AE<I8W6/M@YL=M.8H92Z5K3YS6@.?5KB/J%*#WUR?^G]GKN&Q
MQD^Z5'MLB33^>>XF#C,;5.Q2#E-96LNG$P,E*6)09)-9JHX(T`P@X<FZ380%
M0P'$`#79G<S;>V,KB(+[=;S%MS%R.GD8!H\=/2UGA-0*_P`+15W"H7G=V<WC
MO7!YVYQ6QH_.W?F8Q;12.()B+GASI/$"TN`!\3C1NKJ&E%;9/_L_7<)DEF^O
MF4.[>&L&7)E,[N60F*Y8K.U<R!B&,""UUD+$WD54B*B!"F^'`!">!=@`NM*V
MWJ7VQBGMQV(PDD6%CH&ECXXR&^T1!A%::_W./XKHR\]&N],[&_,;@W'%-N27
MQ/#XI907>PSNE#B*\_*`IP')6\Y.[@6GIF]@F,WF6U(FTY)HV.:AC6$@89TL
M6.NF1HROHLNFR<*MF[Q.!35:F776%$AB(@`"!3&`0TCB=LO[M]RKN/"!\.*N
M;N6=SW@=44#GDU(!(Z]0`*G7VT72F>WC'V([.V$FXC'<9VTL8;:.-CCTSW+(
MP-"0'>6.DN<[I!IR!(5`_:MVT=Q/K.9-N.:NY3+=GAL-5*948E3AS@9(LH[$
M7)*;CF&>`M"036*8*@+EZHBX4_O93E4.ISEZ4WENS:W8?$08#:EE#)GIXZ^(
M?PC3S9WCQN+B/"T$#B00!0\==O=A[V]4&>N=T[ZR4\6V+:7IHS^9VHAMF.K'
M&&M-7/+7$#I!#BZHN5'T(NP4:^:'"M7XLB9+D"SA=W_QDH],2BJ5$4AA>83#
MS;"T$.8/#;AK0X]1O<G[K[CS;;RJU\OR1T\?;7J]WU<%T_\`\HW:#[/[7R;W
MSZ?W?N'=?"E:4Z/?]%/DJ,.[+M;S[Z-^;Z-F7`N3)N1QS9Y0[2N3[@Q&RSEV
MP)YY]0<B0K8Q(N9;.F`&.DJ"?26(4Q@(DH4`'HG96\-M]]MOW&!W+:1MRL3*
MR,&M`=!-`\U<T@Z$5J"1JX%<E=Q.WV\O3'NNTW/M"_E?@[B0B.0Z$N;JZWN6
M#PR`MJ0:=+@":-(6@S^U2QC_`&>_ZZWD4?C'E?E'Y`ZQ]_QFY/+?*?6Y^I\,
M\S_3NIS=3X9[_P!_AKF3]G<O^YW[?]7]"OF^=_\`EX^93AU4\%.'F:<%V7_S
M"8#]F/W4Z!]ST^3]M7_[W#R:_P`E?ZE>/E:\5:]K32Z)6?CO$O+S,G<:]KT$
M)GK6`>,<?UY!)3G2=2/FBD?K(!QY5'$DYZ1OK%$-?1&.EM3S5-QJ5;#;[SC[
MLB[6'EQN*IR5+#](;*R)6*8><FY;9)`K9F0=P%]/3KH``1W`@JB8WNE'5VVU
MM^_W9GK?`XP`W=S(&@G@T<7.=[FM!)_#BL;WENS%[&VQ=[IS)/V-I%U$-^I[
MB:-8T?S/<0![*U.@68"Q_M"_=*\OPSE8QUC6&H*+HXH4:11>2+UXQ(;9(LA9
M2]-XB\43V%04"@F!A]T-MM=FVOIBVA'C/M[RZNWY,MUE!#0T\RUFH(]E=:<5
MYW7WK1W[)F?NK"SL8\.'_P!AS7.+F\NJ6H<"1QZ0*'@*+1=VK]S./O4=[5)6
MUQ$8,`YFV\U0KW5'BQ7JM3N35BW7$J:X%3\VQ$KQJ^:*;`(IG*4WOE-KD_N'
ML6_[>[D?A+QPEA+1)%(!3S(W$@$CDX$%KA[14:$+NOM-W-Q?=?:+-R8]AAN&
MO,4\)-3%,T`D`Z5:YKFO::?2ZAU!55>'+/*]OO<-".),%FAZQ:W%4LR`\%#Q
M+ET$=()F#B`BHD)#@.W#6&N`<RG-;);5IJ5I&152<(I+H*$5073(LBJF(&34
M24*!TE"&#<#$.00$!#Q#7S*JJZ_4I_JAJWZ8(_P-]58^:E=P73]-#^JVZ_I>
M3_(C:A)Q1O!62ZIJ950^IY^;\6\-_P"GS&WY?*ZK1<W<PI')T_3;B6K/"4[)
MIIB#N7O,@+A8Q``QTF<9%HMDBFVW,DD)SB'\HYM2R?4HMX*PO5-3*J;U/_S7
MB/[9"TA_X:)'56/FI'<4XOIK?U-6C].GG^;(_4)>(^"-2$]83`.3^XOLZE:/
MB&KO[G=6EZIDXSK<7T/.2#1I(B@_.F9PJBF!6;9R*IMS![I!UM[L9N7$;6WV
MS(9R9MO8.MY6&1U:-);I6E>)%/FN?_4OL[/;W[928G;=N^ZRC;N"01LIU.:'
M4<14@>$'J.O`*+'H:=M/<'VTP.>X#.F*K!CD;%+U"8KSF:%J*<N"3.19OD&_
ME7"X`=D**9C;[<%0UF7J'W9MC=ESC+G;EY%=>5'*UX97PU+2*U`XU/X+7_I,
MV+O+8EGF+/=F/GLO/DA?&9*4?1KFN`H3]-!7XA7[:YK78:-$1HB_,X")3@`<
M1*8`_*(;!^_J`.NJ@:T*Q18>].#O9KW>K3,CS';_`'!C28[.8V9Y/JFCO)MX
M,9YR[^(G`KTRO0Z!P-]W?8?#7?\`G>Z?;^YV#/BX,E`Z_=CO+#!U5+^@#IX4
MK5>5VV.Q_=2R[HVV<NL-=,QC,MYAD/3TB/S2[J^JM*:\%MAUP"O5)5+>L]@G
M+7<3V@1^/\+TF4OUQ1S'1K"I!1`H`[)#1L5;&[Y^/F%44Q1;+/TBF][?WPUN
MCL/N/";7WP[)9ZX9;6)L96=3JT+G.C(;H#Q`/X+G3U/[2W%O3MJS#[8M9+S)
M#)0R>6RG5T-CF:7:D"@+F@Z\U&_T,NUC/_;+!]P+7.>-)O'2UJF:>XKZ<R+4
M1DTH^.?I/%&_EEUPY&ZBQ0'?;B.LK]0^\-M;MN<:_;MW'=-A9*']%:-)+:`U
M`XT6$>DSM_O#8MGEX]V6,UD^XDA,?F4\0:'UI0GA45^*LL]0K'ESRSV8Y]QU
MCV`=VBYVJHM(^OP#$4P=R;LECA'AT4!5.FF!BMFQS\3!P+K4_;#*6&&W[C,K
MDY6PX^&8N>]W!H,;Q4\^)`^:WEWHPN4W'VNS.$PL+KC*7%L&QQMI5Y$L;J"M
M.0/X*A7T;_3^[D\&=V1LGYXPO8Z-"P-`L+*OS$T6/4:?&9I,K%1,G1<KG(Y%
MIS<H@'`!\==(]]NY>U-Q;+_2=NY"*XN)+EA>UG57I9K74#2M-%R#Z8^S>]]I
M=Q#G]VXNXM+6*TE$;Y`WIZWCITHXZ]-:+5K^3C]>VWT]FN,J47H=[BLUWK=]
MN'>'W194Q/7,*XCMMYQA0J@\D5WD6+$(XUVFY!<CU4H.72!S+(PJ+=(>`AN`
MZZN]/NZ=B[/P][<Y^]AM\M<SAM'5ZO)8W0:`Z=1<5PQZK-D=R]_Y_'V.U\;<
MW>!M+8N)9T])G>X]7%P-0P,'XI@.TQ;UA^SG$B.',7]GZ#JMIV*7LZCN<CV*
M\DXDYHC)-V==5.2*538C!,"CMX!MK)M[#L=OK-G.Y?.4NC$V.C'$-#65I0=.
MGU&JP[MR_P!2W;+;8VS@MMEUD)WRU?&PN+GAH-3Y@Y-`'N4F?UK_`%S?_P`<
MP/\`Z4U_]SUB0V7Z>>>=D_S'_P`*SP=Q?5?P_P!-,_\`2;_\BBWW=(>K_P!Y
MF+D\492[/$&D(WGHVQ,Y&"CX]"49OXTXB7RZRLB8$TW"1S)J;>)#"&LPV0[L
M?L/,',XC.UG,;F$/<XM<UWM'3R.H]ZP#N0SU)=T,`-OY_;73:ME;(',8T/#F
M\P?,/$5!'L4&O[/SU,?P5_!+]7*^?)OXC_B-\.\S'<OQ_P"`?`O-]#XAT?\`
M%/=YO']S6Q/W.[3?KWZ_^J6WW_VGD5H[Z/,Z^/3[>2U)^S/?;_2O^E?T2\_2
M_OON>FK/[GE>76G52G3S]NBVV9OR`VQ?BF[75PH":L1!/1CB=0J:J\HX1,WC
MTD.;[ZWF5`,!0W$0*.O.9HJX#DO74F@5-_8;CUSDC/)[G-)B]8TI-Y;)!RH0
M.1S9W[@1C1$=P$C@C]R9V'`=^F.J[W4;TC@I&BIJIP^J!V^W'N6[,<JXWQ\B
MH^NJ2<9:Z]#)'Y#S[RMN_.+0I!$Y`,L[8F5Z1=C=18I"`41$-MA]H=SV.TM^
MV65R1#;`ET;W?R"04ZS[@ZE>%!4K3W?S9N3WUVPR&$PX<_)MZ)HV#C(8G=18
M->+FUH.;J#FOY_,K7YZ#F'M<FH26B+!'/5(U_"R4<[9RS&01/TE63EBX1(X2
M<IJ<!(8H&W]FO2^&YMKB!MS!(R2V>T.#FN!:6GF"#2GOJO&NYL;VRNWV5U%)
M'>,<6NC<TM<'5H06GQ`UY4JMJOH8]LN1\!=L=DLN3X:1J\UF"WDM4+5Y5([6
M08U-G$LF,1)2#%399B[F%065*FH4I_+](PA[P:X%]1&[<5N7=\-GB'LFAL8/
M+?(TU:9"XES6D:.#=!4:=50O4[TE;"S>SMASW^>C?;W>3N1*R)^CFPM8UK'.
M:=6EYZB`0#T])YKQ_40Q>-3RPROC!J*,-D&/!1RJBF9-).RQP&3>@901]YT]
M;\JX_5MK0T;A2G,+J<BFHX%62]FN3@R;@>J.7"X+3-53^3IH!-NIUX9%$K%4
M0'WQ*K%*HASC]\Y3<1'?5-XH5.TU"8[U*A`,0U;],$0X\/\`F_U_3?48^:@Y
M=/TS]_PMNVX?Z7DV_P"YFTDXJ##5JLFU34ZJA]3P-X_%O_7YGC_V4-5HSH0I
M')_?3X_U=XS](IW_`)9/4LG'Y*+>"G#JFIE5+ZG_`.:\1_\`F-I_R6)U5CYJ
M1W%.+Z:W]35H_3IY_FR/U"7B/@HL4P,X8Y7RWB#(V-F=@F:I(7*H3D'%6>`D
MW\/,U^6>L%DHN9CY&,<-7K=>.?"FJ'(<NX%V'@(ZNFWLHS"9NURLD<<T,$['
MNC>UKF/:'`N:YK@0014:A6#=F$?N/;5]@HII;>>ZMI(V2QN<Q\;W-(8]KFD$
M%KJ'0\J+$[VI]Y^?NQ;O3;L.XV]98L5;JT],8VRW5+=<;3:4XV->.2-5;!'1
MD[*NT%'$2Y01>)+)$$ZK3G!+FYP`>_MY;"VUW%V"9=K6UE%<S1LGMI(XHXRY
MP%>ASF-!`<"6$$Z.I6E%Y8=O>Z6].T_=-L&^+O(36=O,^VNX9999.EI/29&L
M>X@EA#7M<-2RO37JUW+U:U5V[UR%MU1F8^PUFQ1[:5A)J+<)NF$E'NTP50<-
METQ$IBF*/$!V$I@$I@`0$`\\KRSN\?=265]&Z*[B>6O8X4<TCB"%ZQX[(V.6
MLHLEC963V$[`^-[""US3J""/^T<#JE!KYE]JX[_[VP[ZA76B+JD=M7!W2*#A
M!9=H/3=)(K$45;*&3YR)KD(83(G,00$"FV'8=]3ECVAKG`@.X&FA^"IB6-_4
MUC@7-T(!%0:5H?9HL$>),\YV8]_%0KECS;EXD&W[B?A,E"2>3[JK$%:!9G+<
M(YS'KSBC)1F.Y2=(Q!3Y1`-MM>D6;VYMN3MM/=6>/L?/=C.IKVP1!Q/E@]0=
MT5K[ZU7D!MK>.[XN[UM87V5R/V8S/0YCKF8LIYY'207D4_AIPII2BWS;_3\G
M[VO-I>P?^Q4+^OOGF<Q=VZ8NI=*NT_3+I><GHRZ+NI6*6KMA&!J40^!^07L&
M]9/2QCIS-I`8IC=-4Z8>(DX=(>FS;=OF=TWE_?6\<]A;6G21(QKV=<C@1H]I
M'4`PTY@'V%<A^L'>-WMW9=AC,5=36N5NK[K!BD=')Y<4;@:EA!Z"Z1O'0D#F
M$T7[/5D;(F0:_P!RJM_O]WO*D;/4<D<>Y6V>M!XY-:,DC+D8C.2#\695C%`3
M@GR@80#??5Z]3F*QF,NL4,;:P6X=',7>5&Q@<0YM*]#17W5X+'/1GG<WG+'-
M/S-Y=7;F/@#?.E?+2HDKT];C2O.G'3V*UKU-)R;K78AW)3M;FI>O3D;26B\=
M-0,F]AY>/6&T0"0K,9..7;/6:HIJ&+S)G*(E$0WV$=:;[26]M=]Q\5;W<<<M
MNZX(<Q[0YKOZ;S1S2""/<0N@N_-Y=V':'.7=C+)#=LM6EKXW.8]I,T8JUS2'
M`T)&AX*A+T!\EY0R-W*942O^4LF75G"XJ;O(Z,ME]M-CBT'3R=(U5<A'S,H]
M:@N"/`IP*!B_7KI#U*8G$8K:MF<;9VEN^2\HYT<,;'4#":=36@TKRK1<A>CS
M/[@SV]\@,SD+ZZCAL26MEGED94O:*]+W$5`X'DM;(ZXIIRYKT:62_P!?27SU
MBKN$QC=J5D[*=0H-ZQX6.11J5VME:@4K17I)T209BUAI9FR5D%(U5!P<W)SB
M10-Q';7:7ILM]MYO;%WC[^TLY\E;W529(HWO+'M'2:O:2!U!S:5Y+SI]8%UO
M#;F\K'*XF_O[?$WED&@132QQB2-S@YM&O`ZBTM<32I!%>"L?]#/N<5S?VM25
M"MMOEK-D_$MJ?LIA2RS+V9GWM6G`3>U^44D)5RYD7Z7F"N$3F,8X(B!"B(<Q
M0UJSU#[19M[>#,C8P,AP][""WH8&,$C-'MZ6@`:=)'"NIY+=_I.W\=V[!DQ.
M2N9)\_C[AP>9'N>]T4GBC=U.)<X`];3Q#:`<PKL?'6@5U.@?I]/KT*+AS%\-
MPWWY=N8-^;;?E\?O;>S4*GC310J*TJJJ?4OR8#>,IF*6+@2J2"YK9/D(IN7R
M;0RC6)14*4VY%/-`=38WB40$-5HQS*E<>2?WL(QC\A8/93SUN*4WD-V-D><Y
M3%63C$RF;0S94HE#8R20**!MXE6`=2R&IHHM%`IN;!OOJ13)$/L98YDY]"U2
M5#I[^S->7R]@>5N(<3"(EW`HIR*K0[LHEW'8>;<-7"++92&V-G#<SMM'<6![
M@T_X0:?DK3+@<)/>#(SV=J^_;PD=$PO'P<6U_-+8"E*`%*``4`````````X`
M`!X``!JWJZT'#DHE]ZN+OQ-P78@9MP6G*A_\LAQ*03N#&C$SG?LT-@$0,^9<
MQ!V#P#QU.PT<CN"K[]./**=9R1.8ZD7148V_1Z;J+*J?8@6&$*JJ@@ES&`A!
M>QRSC?;B<Z9"\>&IY!X:^]2-.JG#W\T24NF!GSJ%9+R$A5)J.GSMVR9UEABT
M3&2DSIHI@910R21RFV`!$``1U)&:%3.X54+NQ3N5QOB2#N%1R)*#`)2$FVF8
MF6,W7<M%Q*BL@]:.11!11%<A^04P`FQ@WW$.&IY&DD4X*5I#116'8@[H*GG*
M\3];H$3+NJ]6HLKM];GS<6K)X^6="W08L$??'EY$S*<YS`8Q=O<+MQD<PM%3
MS4X-5"/U,K'`OE,<0C&9C'DO'N9=Q(1S5XBX=L43(@B4[Q)$YQ;"94=@*?8P
M_5MQU/'PU4K_`,T^GIXV^LN,)H5E.=B_F!A9)<J\*=X@E)[.").T5$F:BA5U
MTCH[CS$*(`)3`/@.I9!K7DHMX*P3Z?3VZIJ95#>IC:JW*&QC!1DY%R4M%N[.
MM)L&+YN[7C2G3C$$ROR-U%!:*J*IF`"'Y3^Z/#5:,&A*D=Q3@>FK;JZ7'EKJ
MB\Q&MK$%R4=H1#A\W1D'K1Q%,N5RR:*'*LY2*HF<@B0#<HE'?;AJ63B#[D:K
M.-^&_P#N[:IJ=4G^J7Z4<-WA-%<P8>^%5?N&B62:#TKP?)P63(EDD";>/FU4
M45!:V!FB0$VCT0'F3`$E=R@02[^[/=YY]CR#!9WKFVN]QZ::OMW$ZN8.;"=7
M,Y'5NM:\K>H+T[VO<R,[FVSY<&](V`.KX8[IK1HUY`-)&C1C_9X7:`$9Y,,=
MX/?YZ6MD=8XL$!/PU80DSF?XIRW#2+NFNU]A,JM5IA-<A6/F><#G5B7A2J#M
MU`'PUT]GMD=M>\%HW*P2Q/O"SPW%LYHE`_\`,;36G)LK=.2XQVOW([Q^G^_=
M@[J&:.P$AK:7;'.A)I4^4X$%O&I="^AYU5I<#^TE0"<8B6T]K,RZF`V\PO`9
M*C6$6<>0@#T&\E7G[M/^<`P^\J;W1#[=:>N?2I<F6MEF(Q;G@'P$N^?3(!P]
MRZ"LO6_:"`#(8"1UUS\NYHWAR#H7$:^\I!27JV^H7WJ2(XX[,L!?)*,ZLHQ-
M<(R+?6>5BFRAA0<J/;E*IITZ$3:MU`.==-$KI,2B9+B`!JY0]E.V.P8?U7?N
M2-P8P#Y;G-C:X\0!$VLKZG2A/2>:LMQZC.\_=&<X3MAA_M&2NZ?.8QTLC`=#
MU3/`ACH#4NZ`X4)::A7C^GGVJW[M6PO+0N7<C2&3\NY(M[_(V2K$]D'<L@2Q
MRC%BQ4CF$F__`*?(H-&[$@'75V%543"4"EY2ASQW.WEC=Y9YD^$M66>$M(!!
M`P`-\#27=1:-&U).@X"@-3JNL.R_;W+]O=L26VX[U]_N2^N77-U(YSGCS7M:
MWI:]WB<`&BKC]3JD`"@&5/U/^V7)79[WKV+-$-6Y!3&EKR(URY0+8@R=*5UM
M(KRK6<?U23>I%,E'.8V5$[<I%3D,N@(')OOL'9?:'=V)WQL&/`W$K1E8;4VT
MT=1UD!I8)&@\0YOBJ!H="O/3OYL'/]M>Z<VZ+.W><'<7HN[:4-)C#G/$AB<X
M?2YLA+:$U<VA%032VQE^T78./26;MQ@W(;C)"C-%):L,92)"!<3`H@0P,YPY
M5W(-%W@>X06QU0(.PB8P;CI*3TN;@&0<QN1M1B@[20M=U]/*K-!6G/JI5=(P
M^M;:[L4V1^(O3FND`Q!S!&7TUH_5W23P\!-#34JH;U!VO=1G^@P'?5W,QI\>
MQ5[M*&.L+XH4;/X\\'26#-S*K2WP^2,9VV:R#E<QBJ*\JSE;J*"`$$@!O#MB
M_9VV<E+VZVD_[J>VA\ZZN*@]<Q(;T]3="6CD-&B@XU7-/>>+N!O+#P]V=],-
MG!=W'VUC:=+F]$#&EY>&N\0:YQT)HY[NIU.GI5@O[.MEK&=:_'W&5AL\!"W^
MZV*E2]2C)21;,G]BCV$:^C'+&&2<F3\\Z(_=D'HIF,J.X;$$`WUK+U187+79
MQN7M89),;!%*V1S6ES6$EK@Y]/I%`=30>];I]%6X\#8,RNW[V>*'-74L#HFO
M<&NE#0]I:P'ZG`N&@)/N5P?JPY!QS5>QKN`K]TM\/!R=GIC2/KT(I*1Z5AFY
M%>Q1(L$8J)75\V]3,Y:CU3$3,4B1#CN`EUH[LOC,I>=P\9<V$$DD4,Y<]_2X
ML8T1NJ7.`H#0Z5.I('-=)>HO,83']I<Q99.YBBN;BU:V*,O:))'&5G2&,)ZG
M"HU(!H`>%%G>]`+)E'H7=-D*-NEGA*PK<,7!&P"\Y)LXIF^?QDP20<,DW;Y9
M!OYHS;B1/FYE!X%`1UU!ZE<3D<EL^UFL(9)1!=]3PQI<0US2T&C:FE>)X+BW
MT<YW$8;?MY;Y2XBMW75B6QF1S6!SFO:X@.<0*TX"M3R"VBIJ)K$(JD<BB:A"
MG343,!TU$S@!B'(<HB4Y#E$!`0'80'7!)!!Z75!')>HH(<T.::M(J#Q!]Z@]
MZ@W9I7^]OM\G,8NE&L9=8A4UEQG9')`Y86VM&ZB:"+I4I#+%B)A,W0=E*(;E
M$IAWY`#6P^V6^[GM]N:/+,!?CW^">,?Q1DU)'+J;Q:3[QS6J.\W;"S[J[,FP
M,A:S*QUEM93_``3`$`$\>AX\+Z>X\@L4,#*=X7IB9]+-A%6/$^0(51S$NTY>
M/5<4V]P8KE.X8&64(,-:*_(`W(JF)#&42$"*`":A0V[]N8=C]W=MFWZXKW&2
M`.!:X"6%]-#_`#QO%:&NAU!J"O*^RE[F=A-X_=B*?'YB(N80YI,,\==0?X)8
MW4!%.&A%'#2\'&_[1]"A"MD,M=N,@I92)[.Y*@V]JW@W*@%*`@A%3C-](-1$
MP&$1,Y4#80V`/;SUE?2O,+ESL+E6MM#P;-&2\?%S"&G_`"A=883UNVXLVMW'
M@WF^`\3K>8!AX<&2-+A_G/P7DW3UW\]Y\=$QEV7]LLFWOE@,,9'RLNL;($RR
M4<CTT)!C$13-A#1ZA##]^1%9L0-S&'APKX_TY[;VVS]7W[EV'&Q>)S6_T6$#
MBUSW$N(/_<HX\E\^5]6^\=WO&"[7X%[<O-X6N?6XD:3H'-8UK8Q\7ES1Q*EK
M^I#WL?V>WP3\6)+]<[\8OUE/BGS(\\]\Q=/R?R3\R\_+U_@/#DV\IUOZ-MTO
M>UAG[A[`_<[[C[)G^@?T_P"PZ?+%.CCYOE_[_/ZJ>/CHMB?M3W4_9C[3]1D_
M<[]4_5.KS7=7F</(\W^;R^7T=7@^G5(2[R;GNH[JQ1C#'=15HM;"$B3<3)I5
M&+,5,'"H$$Y42J1R!A.;PYSZYY`Z&:KK<^)RT'1,8SA8N-AXY($6$4P:1K)$
M-MDFC)!-LW)P``]U),`W]NOF.IJJJ]#1$:(C1%^#EN@[;N&CE,JK=T@JW<)'
M#<BJ*Z9DE4S![2G3,(#]FB*@GN7[:;KV^WE2YTQK(J4-67"7K4_$E6.O6'0.
M"N4XN1,W#G9F9K"`-U#>XJD&V^X'`*[7!PUXJF113(P1Z@]/L,8TKF:B$KD\
M5(C,UE1;&7K<P&W3%5^0HJ'BU3DW%3G`41WX#J5T;AJW@HAP.A3YO*)V2W)<
M]B<QF&9960,9<S]*0BTR+F,.YC@5L]11#<?'8H:E_J>]1\*>FJ3N%*G')Q-.
MF*!!QI``"M(9_#M4C<N_**G05`RQP`1XG$P[:@0X\05&H"1#[%_:]-OW<K(5
MO&LG(R"YW3Q\Y69.7+I=4QC'555.Y,<YC&$?;J-7CVIX2O6KV+NW>N2S.=K5
M8H<3,,5.LSDHTS9!T@IRF)S)JIN-_N*"&W$-C#]>I22>*:#5/*6<A3A[LK'F
M`?XKQ`?'\A]02H.@3-.L#=O,F]=R3S'M&>/Y!RL[>O%FJ*J[ITX4,JLNNJ94
M3**J*&$1$1\1U-U."4"]&"P?@NN2\?/U^A4^*FHI8',=)L&R:+QHMRB7J(JD
M5YBB)3"`AX#[="YQ&IT2@">'S38?!=(?R*%]O[NI5%<@70'@"Q/^&'^WI31$
MD;CC_'^1&`Q=[I]4N4>*:B8-;+"1DTDF17;G!`)!NX%`3[<1()1X>.ONL,ID
ML7)YV-N)H)?;&]S#\^DBOS5LR>%P^:B^WR]K;W45#I+&UX%>-.H&GR4?F'8E
MV:QLHI-,>V[$:,DJH10[GY3CU>8Y#D4*/25*H@&QR`.P%`.&LFD[C;[EA^WD
MRMZ81P'F$?F-5AD/:'MA;W!NH<%C6SDU)\EO'X'3\E)2N52JT]B$74JY`5>-
M`2F".KL1'0S(3%+RE,+6.;MT3&`O#?;?6*75[>7TGG7LLLTOM>YSC^+B2LZL
M<=C\9#]OC8(;>#^6-C6-_!H`2@U\M%]B\*QU:M7"*<05LK\+9H5T``YB9^,9
M2\<ML`@`J,WZ+AN8Q0,.PB7</8.OIM+R[L)A<64LD,XX.8XM=^((*^2^L+')
MVYM,C#%/:NXLD:U[3_A<"/R3#U[LV[5*I8/FJO=ON*8NP=1-4)-"G1)UB*I<
MW252(NW51243YAV,4H"`\?'6276^]YWMM]G=9.]?;4ITF5U*'B-#7\UB%EVQ
M[>8Z]_4;+#8Z.]K7J$+*U'`BH('R"7V5L%X?SE"QE=R[CRL9!@H9Z$C%15DC
MRO63!Z"70!RV1YB%34!'W=P_N>&K9AMQ9S;UP^[PEU-;7,C:.<QU"16M"?BK
MON+:.V=VVL=CN2RM[VTB=U,9*WJ:UU*5`Y&FB9F"[`^S*KV&O6RN=N.,H.RU
M2:86*N3<7""RD8>;C%BN&$BR<H."'3<-ER`8OB&X<0'5_N>Y>_;RUEL;O*W<
MEI-&6/8YU6N:X4+2".!"QBS[.]K\?>PY&QPEA%?6TK9(I&,Z7,>PU:YI!T((
M!2\RMVI]N><IUG9\OX?I>1)Z/CDXEC)VB--(N&D<DLNX3:-P46!-%,JSI0WN
ME`1$X[CJVX7>6Z=NVSK/!WUQ:VSG]1;&[I!<0`2=.-`/P5WW%V\V1NV[;?[E
MQEK>WC&!C72MZBUH)(`UH!4GA[4V)/3L['DSD42[8L3I*IF*=)5*O%3524(.
MY#IJ$6*=,Y1X@("`@.KN>Z'<(BAR]Z1_O_\`4K`.R7:9I!;@,:"#4$1Z@^T&
MM5,&+C&$)&1\/%MB,XR*9-8Z.9IB<4VC%D@FV:-DQ.8YQ3002*4-Q$=@\=8-
M-+)/*Z>8]4SW%SC[234GYE;,M[>&T@9:V[0VWC8&M:.`:T4`^0%%W]4U62(N
M^-<?9+C#0V0J55[K%F(HF#.SP<=,I)D5VZG0%\W6.V,?E#<4Q*/#QU<,=ELG
MB)O/Q=Q-;S>V-[F\/;0BOS5JRV"PN>@^US5I;W5O2G3+&UX%?9U`T^5%&A3T
M[NQY54ZRG;!B,RJAQ4.;Y91#F.8>81V!0"AN/V;:RT=T>X8;TC,7O2!3^X5@
M9[)]IG/+S@,;U$U_M#_I4@Z!AK$V*FQ6N-L;TJCI%2Z/-6JY%1+@R6VW35>-
M6R;M8FWL.<P:QC)Y[-9E_7EKNXN#6O\`4>YPK\":#Y!9IA]L;=V_'Y6#L;6T
M:!3^E$QAI[W``GYE.5M]/;JT45]Y45,_99\!_6,FOA_X+=;X9->7^5_Q)Z_1
MZJ?5^1_F;^@^2VVZOFOY_I;=/^ZU7?\`2J8XJYG5%5$:(C1$:(CV_O\`Y?9H
MB\6P_F&7_,WYM=__`&#\P_W@_P"=_;\-_P`+_(WU$<45`>;?E/XO)?ZJ7Q/K
M*=;\,/QKZG-OPY/]$MOJ\O[F^^OH9P_B5)WU#AP^:B@?R?44_-NW,/W?CG+M
MN.VV_O<OU;\?X=5M??\`DH)W*9Y7D1V^'?=#P^+[?\;CO]>FOO\`R12@K/0_
MFMO)^!?N_$?L_C>S4KJZ5K^2)^ZYT>4O^+>)?N^>_D_7[-2**>"&Z?N;=+Q#
M_I/\KPYO;J!X)S3C1G+P^Y[/\-MX#J0UH>*F''DELRVY1VY/`?N\^W\.J8X#
MXH.`2C:;;E^[]TG\;[-0=]14QX+VDMMP^Y^YS?Q?;]NIF<#10'!>HAX%^@>`
M^'M_?U)S4>:[Q/#]W_8#117[I??#Z>T-$7<T1&B(T1&B(T1&B(T1&B(T1&B(
(T1&B(T1?_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
